888 related articles for article (PubMed ID: 19201654)
21. Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis.
Prosperini L; Giannì C; Leonardi L; De Giglio L; Borriello G; Galgani S; Pozzilli C; Gasperini C
Mult Scler; 2012 Jan; 18(1):64-71. PubMed ID: 21828195
[TBL] [Abstract][Full Text] [Related]
22. Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study.
Baldi E; Guareschi A; Vitetta F; Senesi C; Curti E; Montepietra S; Simone AM; Immovilli P; Caniatti L; Tola MR; Pesci I; Montanari E; Sola P; Granella F; Motti L; Ferraro D
Curr Med Res Opin; 2014 Sep; 30(9):1849-55. PubMed ID: 24831186
[TBL] [Abstract][Full Text] [Related]
23. Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis.
Phillips JT; Giovannoni G; Lublin FD; O'Connor PW; Polman CH; Willoughby E; Aschenbach W; Pace A; Hyde R; Munschauer FE
Mult Scler; 2011 Aug; 17(8):970-9. PubMed ID: 21421809
[TBL] [Abstract][Full Text] [Related]
24. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.
Kalincik T; Horakova D; Spelman T; Jokubaitis V; Trojano M; Lugaresi A; Izquierdo G; Rozsa C; Grammond P; Alroughani R; Duquette P; Girard M; Pucci E; Lechner-Scott J; Slee M; Fernandez-Bolanos R; Grand'Maison F; Hupperts R; Verheul F; Hodgkinson S; Oreja-Guevara C; Spitaleri D; Barnett M; Terzi M; Bergamaschi R; McCombe P; Sanchez-Menoyo J; Simo M; Csepany T; Rum G; Boz C; Havrdova E; Butzkueven H;
Ann Neurol; 2015 Mar; 77(3):425-35. PubMed ID: 25546031
[TBL] [Abstract][Full Text] [Related]
25. The role of natalizumab in the treatment of multiple sclerosis.
Coyle PK
Am J Manag Care; 2010 Jun; 16(6 Suppl):S164-70. PubMed ID: 20615052
[TBL] [Abstract][Full Text] [Related]
26. Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study.
Gajofatto A; Bianchi MR; Deotto L; Benedetti MD
Eur Neurol; 2014; 72(3-4):173-80. PubMed ID: 25226868
[TBL] [Abstract][Full Text] [Related]
27. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
Devonshire V; Havrdova E; Radue EW; O'Connor P; Zhang-Auberson L; Agoropoulou C; Häring DA; Francis G; Kappos L;
Lancet Neurol; 2012 May; 11(5):420-8. PubMed ID: 22494956
[TBL] [Abstract][Full Text] [Related]
28. Natalizumab for relapsing-remitting multiple sclerosis.
Horga A; Tintoré M
Neurologia; 2011; 26(6):357-68. PubMed ID: 21193250
[TBL] [Abstract][Full Text] [Related]
29. An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis.
Horga A; Castillo J; Rio J; Tintore M; Auger C; Sastre-Garriga J; Edo MC; Perez-Miralles F; Tur C; Nos C; Huerga E; Comabella M; Rovira A; Montalban X
Rev Neurol; 2011 Mar; 52(6):321-30. PubMed ID: 21387248
[TBL] [Abstract][Full Text] [Related]
30. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.
Gold R; Kappos L; Arnold DL; Bar-Or A; Giovannoni G; Selmaj K; Tornatore C; Sweetser MT; Yang M; Sheikh SI; Dawson KT;
N Engl J Med; 2012 Sep; 367(12):1098-107. PubMed ID: 22992073
[TBL] [Abstract][Full Text] [Related]
31. [Natalizumab as induction therapy in multiple sclerosis].
Corlobé A; Charif M; Mania A; Outteryck O; de Sèze J; Labauge P
Rev Neurol (Paris); 2014 Jan; 170(1):2-5. PubMed ID: 24125463
[TBL] [Abstract][Full Text] [Related]
32. Use of fingolimod in patients with relapsing remitting multiple sclerosis in Kuwait.
Alroughani R; Ahmed SF; Behbehani R; Al-Hashel J
Clin Neurol Neurosurg; 2014 Apr; 119():17-20. PubMed ID: 24635919
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of natalizumab therapy in patients of African descent with relapsing multiple sclerosis: analysis of AFFIRM and SENTINEL data.
Cree BA; Stuart WH; Tornatore CS; Jeffery DR; Pace AL; Cha CH
Arch Neurol; 2011 Apr; 68(4):464-8. PubMed ID: 21482925
[TBL] [Abstract][Full Text] [Related]
34. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
[TBL] [Abstract][Full Text] [Related]
35. Clinical evaluation of natalizumab for formulary consideration.
Bivins A; Hou K; Ayesu N; Ellsworth B; Montenegro S; Tu X; Boyle C; Dowling T; Shaya FT
Expert Opin Biol Ther; 2010 Aug; 10(8):1279-87. PubMed ID: 20626228
[TBL] [Abstract][Full Text] [Related]
36. Severe relapses after the first infusion of natalizumab in active relapsing-remitting multiple sclerosis.
Rinaldi F; Perini P; Calabrese M; Rinaldi L; Gallo P
Mult Scler; 2009 Nov; 15(11):1359-62. PubMed ID: 19812116
[TBL] [Abstract][Full Text] [Related]
37. Natalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy.
Totaro R; Lugaresi A; Bellantonio P; Danni M; Costantino G; Gasperini C; Florio C; Pucci E; Maddestra M; Spitaleri D; Lus G; Ardito B; Farina D; Rossi M; Di Carmine C; Altobelli E; Maccarone B; Casalena A; De Luca G; Travaglini D; Di Ioia M; Di Tommaso V; Fantozzi R; Ruggieri S; Provinciali L; De Riso S; Mundi C; Fuiani A; Galgani S; Ruggieri S; Maniscalco GT; Giuliani G; Cartechini E; Petretta V; Fratta M; Alfieri G; Gatto M; Carolei A;
Int J Immunopathol Pharmacol; 2014; 27(2):147-54. PubMed ID: 25004826
[TBL] [Abstract][Full Text] [Related]
38. Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients.
Kerbrat A; Le Page E; Leray E; Anani T; Coustans M; Desormeaux C; Guiziou C; Kassiotis P; Lallement F; Laplaud D; Diraison P; Rouhart F; Sartori E; Wardi R; Wiertlewski S; Edan G
J Neurol Sci; 2011 Sep; 308(1-2):98-102. PubMed ID: 21665227
[TBL] [Abstract][Full Text] [Related]
39. Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosis.
Zhao Y; Traboulsee A; Petkau AJ; Li D
Neurology; 2008 Mar; 70(13 Pt 2):1092-7. PubMed ID: 18003938
[TBL] [Abstract][Full Text] [Related]
40. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Kappos L; Radue EW; O'Connor P; Polman C; Hohlfeld R; Calabresi P; Selmaj K; Agoropoulou C; Leyk M; Zhang-Auberson L; Burtin P;
N Engl J Med; 2010 Feb; 362(5):387-401. PubMed ID: 20089952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]